Ania M. Fiksinski

Ania M. Fiksinski

Auto-generated profile, based on publicly available information

Ania M. Fiksinski

Department of Pediatrics, Wilhelmina Children’s Hospital, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RDRobert W. Davies
Robert W. Davies
AFAnia M. Fiksinski
Ania M. Fiksinski
EBElemi J. Breetvelt
Elemi J. Breetvelt
NWNigel M. Williams
Nigel M. Williams
SHStephen R. Hooper
Stephen R. Hooper
JVJacob Vorstman
Jacob Vorstman

3 February 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
ICIsabelle Cleynen
Isabelle Cleynen
WEWorrawat Engchuan
Worrawat Engchuan
MHMatthew S. Hestand
Matthew S. Hestand
THTracy Heung
Tracy Heung
AHAaron M. Holleman
Aaron M. Holleman
ABAnne S. Bassett
Anne S. Bassett

29 July 2019 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JVJulio E. Villalón-Reina
Julio E. Villalón-Reina
KMKenia Martínez
Kenia Martínez
XQXiaoping Qu
Xiaoping Qu
CCChristopher R. K. Ching
Christopher R. K. Ching
TNTalia M. Nir
Talia M. Nir
CBCarrie E. Bearden
Carrie E. Bearden
22q11.2 deletion syndrome (22q11DS)—a neurodevelopmental condition caused by a hemizygous deletion on chromosome 22—is associated with an elevated risk of psychosis and other developmental brain disorders. Prior single-site diffusion magnetic resonance imaging (dMRI) studies have reported altered white matter (WM) microstructure in 22q11DS, but small samples and variable methods have led to contradictory results. Here we present the largest study ever conducted of dMRI-derived measures of WM microstructure in 22q11DS (334 22q11.2 deletion carriers and 260 healthy age- and sex-matched controls; age range 6–52 years). Using harmonization protocols developed by the ENIGMA-DTI working group, we identified widespread reductions in mean, axial and radial diffusivities in 22q11DS, most pronounced in regions with major cortico-cortical and cortico-thalamic fibers: the corona radiata, corpus callosum, superior longitudinal fasciculus, posterior thalamic radiations, and sagittal stratum (Cohen’sd’s ranging from −0.9 to −1.3). Only the posterior limb of the internal capsule (IC), comprised primarily of corticofugal fibers, showed higher axial diffusivity in 22q11DS. 22q11DS patients showed higher mean fractional anisotropy (FA) in callosal and projection fibers (IC and corona radiata) relative to controls, but lower FA than controls in regions with predominantly association fibers. Psychotic illness in 22q11DS was associated with more substantial diffusivity reductions in multiple regions. Overall, these findings indicate large effects of the 22q11.2 deletion on WM microstructure, especially in major cortico-cortical connections. Taken together with findings from animal models, this pattern of abnormalities may reflect disrupted neurogenesis of projection neurons in outer cortical layers.

1 October 2017 in Schizophrenia Research
Verified
Journal Article
Closed access
AFA.M. Fiksinski
A.M. Fiksinski
EBE.J. Breetvelt
E.J. Breetvelt
SDS.N. Duijff
S.N. Duijff
ABA.S. Bassett
A.S. Bassett
RKR.S. Kahn
R.S. Kahn
JVJ.A.S. Vorstman
J.A.S. Vorstman

8 September 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AFAnia M. Fiksinski
Ania M. Fiksinski
MSMaude Schneider
Maude Schneider
CMClodagh M. Murphy
Clodagh M. Murphy
MAMarco Armando
Marco Armando
SVStefano Vicari
Stefano Vicari
JVJacob A. S. Vorstman
Jacob A. S. Vorstman

3 October 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AFAnia M. Fiksinski
Ania M. Fiksinski
GHGil D. Hoftman
Gil D. Hoftman
JVJacob Vorstman
Jacob Vorstman
CBCarrie E. Bearden
Carrie E. Bearden
Recently, increasing numbers of rare pathogenic genetic variants have been identified that are associated with variably elevated risks of a range of neurodevelopmental outcomes, notably including Autism Spectrum Disorders (ASD), Schizophrenia Spectrum Disorders (SSD), and Intellectual Disability (ID). This review is organized along three main questions: First, how can we unify the exclusively descriptive basis of our current psychiatric diagnostic classification system with the recognition of an identifiable, highly penetrant genetic risk factor in an increasing proportion of patients with ASD or SSD? Second, what can be learned from studies of individuals with ASD or SSD who share a common genetic basis? And third, what accounts for the observed variable penetrance and pleiotropy of neuropsychiatric phenotypes in individuals with the same pathogenic variant? In this review, we focus on findings of clinical and preclinical studies of the 22q11.2 deletion syndrome (22q11DS). This particular variant is not only one of the most common among the increasing list of known rare pathogenic variants, but also one that benefits from a relatively long research history. Consequently, 22q11DS is an appealing model as it allows us to: (1) elucidate specific genotype–phenotype associations, (2) prospectively study behaviorally defined classifications, such as ASD or SSD, in the context of a known, well-characterized genetic basis, and (3) elucidate mechanisms underpinning variable penetrance and pleiotropy, phenomena with far-reaching ramifications for research and clinical practice. We discuss how findings from animal and in vitro studies relate to observations in human studies and can help elucidate factors, including genetic, environmental, and stochastic, that impact the expression of neuropsychiatric phenotypes in 22q11DS, and how this may inform mechanisms underlying neurodevelopmental expression in the general population. We conclude with research priorities for the field, which may pave the way for novel therapeutics.